Compare Abeona Therapeutics Inc (ABEO) vs Cronos Group Inc (CRON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Cronos Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Cronos Group Inc trades at $2.76 (market cap $1.03B). The key difference: Cronos Group Inc is far larger — about 2.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CRON | |
|---|---|---|
Market Cap | $373.32M | $1.03B |
Sector | Health | Health |
52-Week High | $7.23 | $3.27 |
52-Week Low | $4.17 | $1.95 |
Enterprise Value | $228.22M | $205.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Cronos Group (CRON) trades at $2.75, down 3.85% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue growth of 40% year-over-year to $45.2 million, achieving record net revenue and gross profit. However, net income remains negative at -$9.45 million for 2025, though margins have improved significantly from prior years. Recent news highlights expansion in Canada and Israel, along with a share repurchase program extension.
Outlook is cautiously optimistic with strong revenue growth and market share gains, but profitability challenges and intense cannabis competition pose risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include international expansion and execution on cost controls, while regulatory uncertainty and cash flow volatility remain headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
